Company profile
AMGEN INC
NASDAQ:AMGNBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (47)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Apremilast | approved | — | 45 | approved |
| BRODALUMAB | approved | — | 6 | approved |
| Carfilzomib | approved | — | 24 | approved |
| Cinacalcet hydrochloride | approved | — | 4 | approved |
| Daraxonrasib | approved | — | 13 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (945)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00840333 | phase1 | completed | 2009-04-01 | 2009-12-01 | Amgen | "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients" |
| NCT00527085 | phase2 | completed | 2001-10-01 | 2003-08-01 | Amgen | 12-month Study of AMG 073 in Renal Osteodystrophy |
| NCT00356356 | phase3 | completed | 2002-04-01 | 2006-08-01 | Amgen | 16.0040 Ankylosing Spondylitis Study |
| NCT00803712 | phase4 | completed | 2009-02-01 | 2010-12-09 | Amgen | 20070360 Incident Dialysis |
| NCT01568216 | phase2 | terminated | 2012-05-01 | 2013-06-01 | Amgen | 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms |
FDA applications (30)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 103234 | BLA | Amgen Inc. | ||||
Loading… | ||||||
| BLA 103353 | BLA | Amgen Inc. | ||||
Loading… | ||||||
| BLA 103951 | BLA | Amgen Inc. | ||||
Loading… | ||||||
| BLA 125031 | BLA | Amgen Inc. | ||||
Loading… | ||||||
| BLA 125147 | BLA | Amgen Inc. | ||||
Loading… | ||||||